ChemoCentryx Inc (CCXI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ChemoCentryx Inc stock (CCXI) is currently trading at $10.17. ChemoCentryx Inc PS ratio (Price-to-Sales) is 100.30. Analyst consensus price target for CCXI is $52.00. WallStSmart rates CCXI as Sell.
- CCXI PE ratio analysis and historical PE chart
- CCXI PS ratio (Price-to-Sales) history and trend
- CCXI intrinsic value — DCF, Graham Number, EPV models
- CCXI stock price prediction 2025 2026 2027 2028 2029 2030
- CCXI fair value vs current price
- CCXI insider transactions and insider buying
- Is CCXI undervalued or overvalued?
- ChemoCentryx Inc financial analysis — revenue, earnings, cash flow
- CCXI Piotroski F-Score and Altman Z-Score
- CCXI analyst price target and Smart Rating
ChemoCentryx Inc
📊 No data available
Try selecting a different time range
Smart Analysis
ChemoCentryx Inc (CCXI) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
ChemoCentryx Inc (CCXI) Key Strengths (3)
Revenue surging 549.00% year-over-year
84.39% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
ChemoCentryx Inc (CCXI) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 100.3x annual revenue
Very expensive at 15.8x book value
Supporting Valuation Data
ChemoCentryx Inc (CCXI) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 549.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (100.30), Price/Book (15.81) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -47.00%, Operating Margin at -353.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -47.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 549.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CCXI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CCXI's Price-to-Sales ratio of 100.30x trades 59% above its historical average of 63.17x (80th percentile), historically expensive. The current valuation is 47% below its historical high of 187.66x set in Jun 2013, and 1104% above its historical low of 8.33x in Feb 2018. Over the past 12 months, the PS ratio has expanded from ~22.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for ChemoCentryx Inc (CCXI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ChemoCentryx Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 37M with 549% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 549% YoY, reaching 37M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 39% of revenue (14M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -27M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can ChemoCentryx Inc maintain 549%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ChemoCentryx Inc.
Bottom Line
ChemoCentryx Inc is a high-conviction growth story with revenue accelerating at 549% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ChemoCentryx Inc(CCXI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.